Arcturus Therapeutics Holdings Inc. (NASDAQ:ARCT) Receives $71.40 Consensus PT from Analysts

Arcturus Therapeutics Holdings Inc. (NASDAQ:ARCT) has received a consensus rating of “Buy” from the eight research firms that are presently covering the firm, MarketBeat reports. Seven equities research analysts have rated the stock with a buy recommendation and one has issued a strong buy recommendation on the company. The average twelve-month target price among brokerages that have issued ratings on the stock in the last year is $71.40.

Several research firms have issued reports on ARCT. Cantor Fitzgerald reiterated an “overweight” rating on shares of Arcturus Therapeutics in a research report on Monday, September 9th. Leerink Partnrs upgraded shares of Arcturus Therapeutics to a “strong-buy” rating in a research note on Monday, August 12th. HC Wainwright boosted their price objective on shares of Arcturus Therapeutics from $60.00 to $63.00 and gave the stock a “buy” rating in a report on Thursday, August 8th. Finally, Leerink Partners assumed coverage on shares of Arcturus Therapeutics in a report on Monday, August 12th. They issued an “outperform” rating and a $70.00 target price for the company.

Arcturus Therapeutics Stock Down 2.0 %

Shares of NASDAQ:ARCT opened at $20.61 on Monday. The company has a market cap of $555.07 million, a price-to-earnings ratio of -5.27 and a beta of 2.60. Arcturus Therapeutics has a fifty-two week low of $17.52 and a fifty-two week high of $45.00. The firm’s 50-day simple moving average is $21.16 and its 200-day simple moving average is $27.07.

Arcturus Therapeutics (NASDAQ:ARCT) last announced its quarterly earnings data on Monday, August 5th. The biotechnology company reported ($0.64) earnings per share for the quarter, beating analysts’ consensus estimates of ($1.85) by $1.21. The company had revenue of $49.86 million for the quarter, compared to analyst estimates of $21.00 million. Arcturus Therapeutics had a negative return on equity of 25.47% and a negative net margin of 41.21%. During the same quarter in the previous year, the company earned ($1.98) EPS. On average, research analysts forecast that Arcturus Therapeutics will post -2.6 EPS for the current year.

Institutional Trading of Arcturus Therapeutics

Large investors have recently modified their holdings of the business. Nordea Investment Management AB acquired a new stake in Arcturus Therapeutics during the 1st quarter valued at $1,846,000. Sumitomo Mitsui Trust Holdings Inc. increased its position in Arcturus Therapeutics by 22.4% during the 2nd quarter. Sumitomo Mitsui Trust Holdings Inc. now owns 1,563,065 shares of the biotechnology company’s stock worth $38,061,000 after purchasing an additional 286,546 shares in the last quarter. Campbell & CO Investment Adviser LLC acquired a new position in Arcturus Therapeutics in the 4th quarter valued at about $927,000. Hennion & Walsh Asset Management Inc. lifted its holdings in Arcturus Therapeutics by 2.5% in the 1st quarter. Hennion & Walsh Asset Management Inc. now owns 31,930 shares of the biotechnology company’s stock valued at $1,078,000 after purchasing an additional 778 shares in the last quarter. Finally, Wellington Management Group LLP grew its holdings in shares of Arcturus Therapeutics by 40.3% during the fourth quarter. Wellington Management Group LLP now owns 60,841 shares of the biotechnology company’s stock worth $1,918,000 after buying an additional 17,491 shares in the last quarter. 94.54% of the stock is currently owned by institutional investors and hedge funds.

About Arcturus Therapeutics

Arcturus Therapeutics Holdings Inc, a late-stage clinical messenger RNA medicines and vaccine company, focuses on the development of infectious disease vaccines and other products within liver and respiratory rare diseases. Its technology platforms include LUNAR lipid-mediated delivery and STARR mRNA.